Abstract
The aim of this study was to determine whether or not statins influence biochemical recurrence (BCR) in Korean patients undergoing surgical treatment for prostate cancer. We reviewed data from 687 men who underwent radical retropubic prostatectomy and who did not receive neoadjuvant treatment. Of these patients, 87 reported the use of preoperative statins at surgery. BCR-free survival was determined after exclusion of 78 patients with lymph node metastases and/or who received immediate adjuvant treatment. Patients on statin therapy were more likely to have a co-morbid disease (P<0.05). Mean PSA (9.6 vs 13.6 ng ml−1, P=0.002) and PSA density (0.27 vs 0.38 ng ml−1 ml−1, P<0.001) were significantly lower in patients on statins. However, in the multivariable linear regression model, statin use was not associated with a decrease in PSA. Overall BCR for the entire cohort was not significantly different between the statin and nonstatin groups. On multivariate analysis, positive surgical margin and seminal vesicle invasion were independent risk factors for BCR-free survival, whereas other variables, including statin use, were not significant in predicting the risk of BCR. Patients with positive surgical margin and seminal vesicle invasion had a 2.1- (odds ratio, 2.15; 95% confidence interval, 1.29–3.57; P=0.003) and 2.2-fold risk (odds ratio, 2.21; 95% confidence interval, 1.25–3.89; P=0.006) of BCR. Preoperative statin use is not associated with reduced BCR following radical prostatectomy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–1278.
Blais L, Desgagne A, LeLorier J . 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000; 160: 2363–2368.
Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS et al. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 2184–2192.
Chan KK, Oza AM, Siu LL . The statins as anticancer agents. Clin Cancer Res 2003; 9: 10–19.
Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM . Statins and cancer prevention. Nat Rev Cancer 2005; 5: 930–942.
Cyrus-David MS, Weinberg A, Thompson T, Kadmon D . The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol 2005; 173: 1923–1925.
Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ . The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 2008; 100: 1511–1518.
Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98: 1819–1825.
Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE . Cholesterol-lowering drugs and advanced prostate cancer incidence in a large US cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: 2213–2217.
Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, Haque R et al. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: 2218–2225.
Murtola TJ, Tammela TL, Lahtela J, Auvinen A . Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007; 16: 2226–2232.
D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969–974.
Chen ME, Johnston D, Reyes AO, Soto CP, Babaian RJ, Troncoso P . A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume. Am J Surg Pathol 2003; 27: 1291–1301.
Werny DM, Saraiya M, Gregg EW . Prostate-specific antigen values in diabetic and nondiabetic US men, 2001–2002. Am J Epidemiol 2006; 164: 978–983.
Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D’Amico AV, Dmochowski RR . Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007; 177: 540–545.
Jakobisiak M, Golab J . Potential antitumor effects of statins (Review). Int J Oncol 2003; 23: 1055–1069.
Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ . The risk of cancer in users of statins. J Clin Oncol 2004; 22: 2388–2394.
Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005; 162: 318–325.
Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005; 114: 643–647.
Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL . Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 2008; 168: 250–260.
Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007; 357: 1477–1486.
Banez LL, Klink JC, Jayachandran J, Lark AL, Gerber L, Hamilton RJ et al. Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2010; 19: 722–728.
Soto DE, Daignault S, Sandler HM, Ray ME . No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. Urology 2009; 73: 158–162.
Moyad MA, Merrick GS, Butler WM, Wallner KE, Galbreath RW, Kurko B et al. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 2005; 66: 1150–1154.
Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL . Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 2010; 28: 2653–2659.
Loeb S, Kan D, Helfand BT, Nadler RB, Catalona WJ . Is statin use associated with prostate cancer aggressiveness? BJU Int 2010; 105: 1222–1225.
Krane LS, Kaul SA, Stricker HJ, Peabody JO, Menon M, Agarwal PK . Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen. J Urol 2010; 183: 118–124.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Ku, J., Jeong, C., Park, Y. et al. Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients. Prostate Cancer Prostatic Dis 14, 63–68 (2011). https://doi.org/10.1038/pcan.2010.39
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/pcan.2010.39
Keywords
This article is cited by
-
Impact of statin use on overall and time to biochemical failure following radical prostatectomy or radiation therapy
World Journal of Urology (2021)
-
The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis
Scientific Reports (2016)
-
Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis
Prostate Cancer and Prostatic Diseases (2016)
-
Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy
World Journal of Urology (2015)
-
Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study
Prostate Cancer and Prostatic Diseases (2013)